The purpose of this clinical trial is to determine if HCQ in a dose of 400mg daily and
indapamide in a dose of 2.5mg daily can help in reducing the progression of disability in
people with secondary progressive multiple sclerosis.
The number of participants in this study will be 35. A maximum of 42 people with SPMS will be
included. The trial is funded through internal funding through the University of Calgary.
There is no sponsorship from any pharmaceutical industry.